Marisa Wexler, MS, senior science writer —

Daratumumab, which is approved to treat some cancers, was effective at controlling cold agglutinin disease (CAD) in an elderly woman who failed to respond to rituximab, a study reports. The report, “Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature,”…

A man had stroke-like symptoms, a heart attack, and rotting skin that were determined to be likely caused by cold agglutinin disease (CAD). While similar issues have been reported with CAD, this may be the first report of these symptoms occurring at the same time in one patient, the…

A case of cold agglutinin disease (CAD), found to be secondary to a type of blood cancer called B-cell lymphoma, successfully resolved after the cancer was appropriately treated, a study shows. The case report illustrates the importance of identifying the underlying cause of CAD so treatment can be given,…

Specially designed miniaturized antibodies, or nanobodies, reduced blood cell destruction in a new mouse model of a disease similar to cold agglutinin disease (CAD), a study showed. These findings suggest that the nanobodies, designed to suppress the complement cascade by blocking the complement component 2 (C2) protein, could…

Long-term treatment with Enjaymo (sutimlimab-jome) in people with cold agglutinin disease (CAD) results in rapid and sustained reductions in red blood cell destruction and anemia, as well as clinically-meaningful reductions in fatigue. That’s according to 2.5 years of data from the Phase 3 CARDINAL clinical trial, which tested…

An experimental treatment called HMBD-011, designed to target self-reactive antibodies and the immune B-cells that produce them, showed efficacy in a cellular model of cold agglutinin disease (CAD), according to new preclinical findings presented at a scientific conference. “HMBD-011 is a potentially first-in-class … antibody developed for treatment for…

A Phase 1 trial testing Annexon Biosciences’ oral treatment candidate ANX1502 — for complement-mediated autoimmune disorders such as cold agglutinin disease (CAD) — in healthy volunteers has moved to its multiple-dosing phase. The company is planning to launch a proof-of-concept study of ANX1502 in people with CAD later…

Note: This story was updated Jan. 30, 2023,  to correct that the CARDINAL trial did not include a placebo group. The U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Enjaymo (sutimlimab-jome) to include cold agglutinin disease (CAD) patients without a history of…

Special considerations should be taken when preparing a blood transfusion for someone with cold agglutinin disease (CAD), a recent study indicates. The study, “Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies,” was published…

People with cold agglutinin disease (CAD) reported clinically significant improvements in health-related quality of life after treatment with Enjaymo (sutimlimab-jome), according to a new analysis of data from the Phase 3 CADENZA clinical trial. These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA…